Tracking Real-World safety of treatments for a rare bleeding disorder

NCT ID NCT03853486

Completed Knowledge-focused Sponsor: American Thrombosis and Hemostasis Network Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study follows people with severe von Willebrand disease (VWD) to see how well different treatments work and how safe they are in everyday use. Researchers are tracking side effects and how the body responds to therapy given on demand, during surgery, or as regular prevention. The goal is to improve care for both children and adults with this inherited bleeding condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Von Willebrand Factor (VWF) regimens
What this could lead to: If successful, this study could provide better understanding of how to safely use VWF treatments for different situations like bleeding episodes or surgery.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by the small number of participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary von Willebrand disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASES

Contacts and locations

Show contact details

Locations

Bleeding and Clotting Disorders Institute

Peoria, Illinois, 61615, United States
Center for Inherited Blood Disorders

Orange, California, 92868, United States
Children's Healthcare of Atlanta/Emory

Atlanta, Georgia, 30322, United States
Children's Hospital of Michigan Hemostasis and Thrombosis Center

Detroit, Michigan, 48201, United States
Connecticut Bleeding and Clotting Disorders Center

Farmington, Connecticut, 06030, United States
Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, 15213, United States
Hemophilia Outreach Center

Green Bay, Wisconsin, 54311, United States
Indiana Hemophilia and Thrombosis Center (IHTC)

Indianapolis, Indiana, 46260, United States
Louisiana Center for Bleeding and Clotting Disorders

New Orleans, Louisiana, 70112, United States
Mayo Comprehensive Hemophilia Center

Rochester, Minnesota, 55905, United States
Michigan State University Center for Bleeding and Clotting Disorders

East Lansing, Michigan, 48823, United States
Nationwide Children's Hospital Columbus

Columbus, Ohio, 43205, United States
Oregon Health

Portland, Oregon, 91239, United States
Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Rhode Island Hemostasis & Thrombosis Center

Providence, Rhode Island, 02903, United States
University of Colorado Denver Hemophilia and Thrombosis Center

Aurora, Colorado, 80045, United States
University of Florida Hemophilia Treatment Center

Gainesville, Florida, 32610, United States
University of Michigan Hemophilia and Coagulation Disorders

Ann Arbor, Michigan, 48109, United States
University of Tennessee, University Clinical Health (Memphis)

Memphis, Tennessee, 38119, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States
Versiti - Blood Center of Wisconsin

Milwaukee, Wisconsin, 53201, United States
Washington University Center for Treatment of Bleeding and Blood Clotting Disorders

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.